A recent study suggests that patients who come off new slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Research printed in a leading health publication demonstrates that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these drugs must be cognizant of the risk of rapid weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to pre-treatment mass in about 18 months.
Analyzing Therapies
The study, which reviewed 37 of trials involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting.
Researchers point out that individuals who lose weight through diet and exercise generally experience a less rapid creep back—around 100 grams monthly—once they finish.
Explaining the Fast Regain
Experts believe the mechanism of the injections is key to understanding the heightened rebound.
These medications mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the therapy should be considered long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "underscore the long-term nature of excess weight," comparing it to managing conditions like diabetes.
Patient Accounts
People who have discontinued the medication report a intense return of appetite.
"It was like a trigger flipping and you're instantly ravenous," recalled an individual.
The struggle is compounded if users have not developed permanent lifestyle or habit modifications during therapy.
Widespread Interest
Survey data indicate that millions of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is higher among females compared to males.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent solution and maintained weight loss relies on integrated behavioural support.
